文献速递肿瘤 PET/CT核素与放射性配体治疗

111In-PSMA-617在淋巴结转移性前列腺癌中的摄取与病理对照表现

Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-07-30

六例术前PSMA PET/CT怀疑淋巴结转移的前列腺癌患者接受111In-PSMA-617引导下淋巴结清扫,离体测量310枚淋巴结的示踪剂摄取并与病理对照。未受累淋巴结中位SUL为0.16,受累淋巴结为13.2,差异有统计学意义(p<0.0001)。以SUL 1.136为界值,ROC曲线下面积为0.976(95%CI 0.95-1.00,p<0.0001),灵敏度92.1%(35/38),特异度98.9%(180/182)。

要点

  • 111In-PSMA-617在单枚淋巴结水平可区分转移与非转移淋巴结。
  • 未受累淋巴结中位SUL 0.16 vs 受累淋巴结13.2(p<0.0001)。
  • SUL界值1.136时灵敏度92.1%、特异度98.9%、准确率97.7%。

核心结论

  • 离体单枚淋巴结分析显示111In-PSMA-617在本文患者中区分受累与未受累淋巴结的能力优良,该示踪特性是术中实时测量的前提。

研究设计与样本

  • 六例术前PSMA PET/CT怀疑淋巴结转移的前列腺癌患者接受111In-PSMA-617引导下淋巴结清扫,其中挽救性清扫四例、初次清扫两例。
  • 术前48小时静脉注射111In-PSMA-617 109 ± 5 MBq,行小亚区模板清扫,各亚区标本按单枚淋巴结分离。
  • 离体用锗探测器测量摄取,以基于瘦体重的标准化摄取值(SUL)表达,并行ROC分析。

主要发现

  • 共从74个亚区切除310枚淋巴结(平均52 ± 19.7枚),其中35枚病理证实为淋巴结转移。
  • 标本分离后共318份单份标本:182份前列腺癌阴性淋巴结标本含275枚淋巴结、35份单枚转移淋巴结标本、3份非淋巴结前列腺癌组织标本、98份纤维脂肪组织标本。
  • 未受累淋巴结与受累淋巴结中位SUL分别为0.16与13.2,差异有统计学意义(p<0.0001)。
  • 基于38份含肿瘤标本与182份无肿瘤标本的ROC分析,曲线下面积为0.976(95%CI 0.95-1.00,p<0.0001)。

关键数值与推荐

  • SUL界值1.136时,区分受累与未受累淋巴结的灵敏度92.1%(35/38)、特异度98.9%(180/182)、阳性预测值94.6%(35/37)、阴性预测值98.4%(180/183)、准确率97.7%(215/220)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intraoperative identification of lymph node (LN) metastases (LNM) detected on preoperative PSMA PET/CT may be facilitated by PSMA radioguided surgery with the use of a gamma probe. We evaluated the uptake of 111In-labelled PSMA ligand DKFZ-617 (referred to as 111In-PSMA-617) in unaffected LN and LNM at the level of single LN. METHODS: Six patients with prostate cancer (PCa) with suspicion of LNM on preoperative PSMA PET/CT underwent 111In-PSMA-617-guided lymphadenectomy (LA; four salvage LA and two primary LA). 111In-PSMA-617 (109 ± 5 MBq). was injected Intravenously 48 h prior to surgery Template LAs were performed in small subregions: common, external, obturator and internal iliac vessels, and presacral and retroperitoneal subregions (n = 4). Samples from each subregion were isolated aiming at the level of single LN. Uptake was measured ex situ using a germanium detector. Receiver operating characteristic (ROC) analysis was performed based on 111In-PSMA-617 uptake expressed as standardized uptake values normalized to lean body mass (SUL). RESULTS: Overall 310 LN (mean 52 ± 19.7) were removed from 74 subregions (mean 12 ± 3.7). Of the 310 LN, 35 turned out to be LNM on histopathology. Separation of the samples from all subregions resulted in 318 single specimens: 182 PCa-negative LN samples with 275 LN, 35 single LNM samples, 3 non-nodal PCa tissue samples and 98 fibrofatty tissue samples. The median SULs of nonaffected LN (0.16) and affected LN (13.2) were significantly different (p < 0.0001). Based on 38 tumour-containing and 182 tumour-free specimens, ROC analysis revealed an area under the curve of 0.976 (95% CI 0.95-1.00, p < 0.0001). Using a SUL cut-off value of 1.136, sensitivity, specificity, positive predictive value, negative predictive value and accuracy in discriminating affected from nonaffected LN were 92.1% (35/38), 98.9% (180/182), 94.6% (35/37), 98.4% (180/183) and 97.7% (215/220), respectively. CONCLUSION: Ex situ analysis at the level of single LN showed that 111In-PSMA-617 had excellent ability to discriminate between affected and nonaffected LN in our patients with PCa. This tracer characteristic is a prerequisite for in vivo real-time measurements during surgery.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mix M, Reichel K, Stoykow C, et al. Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. Eur J Nucl Med Mol Imaging. 2018. PMID: 30062606. doi:10.1007/s00259-018-4094-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。